The D2EFT study is a phase IIIB/IV randomised open-label trial to compare dolutegravir with pharmaco-enhanced darunavir versus dolutegravir with predetermined nucleosides versus recommended standard of care antiretroviral regimens in patients with HIV-1 infection who have failed recommended first line therapy.
The D2EFT study is a phase IIIB/IV randomised open-label trial to compare dolutegravir with pharmaco-enhanced darunavir versus dolutegravir with predetermined nucleosides versus recommended standard of care antiretroviral regimens in patients with HIV-1 infection who have failed recommended first line therapy.
The major aim of this study is to find the best 2nd line regimen, among the current range of drugs used in our environment that would have maximal benefit for most patients who have failed first line HIV 1 drugs.
This is without the infrastructure of drug sensitivity testing in a resource constrained environment. Its emphasis is finding a regimen that will fulfil criteria including:
- Efficacy at significantly reducing viral load
- Encouraging adherence due to a lower incidence of drug toxicity, drug to drug interactions or other adverse events,
- Improving participant quality of life
The D2EFT study is designed to support HIV treatment in the sub-Saharan African context and will provide knowledge to significantly improve treatment outcomes and change the current strategy for managing patients who have failed 1st line HIV treatment.